ACADIA Pharmaceuticals (ACAD) Expected to Announce Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) is expected to release its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect ACADIA Pharmaceuticals to post earnings of $0.13 per share and revenue of $292.5370 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

ACADIA Pharmaceuticals Stock Performance

ACAD opened at $24.73 on Tuesday. ACADIA Pharmaceuticals has a one year low of $13.40 and a one year high of $28.35. The company has a market cap of $4.18 billion, a P/E ratio of 15.95, a PEG ratio of 8.42 and a beta of 0.66. The business’s 50-day simple moving average is $25.70 and its 200-day simple moving average is $24.44.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Royal Bank Of Canada lowered their target price on shares of ACADIA Pharmaceuticals from $35.00 to $31.00 and set an “outperform” rating for the company in a report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a report on Monday, December 29th. Stifel Nicolaus set a $37.00 target price on ACADIA Pharmaceuticals in a report on Tuesday, December 16th. Mizuho upgraded ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $29.00 to $35.00 in a research note on Monday. Finally, Citigroup boosted their price objective on ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.35.

Insider Activity at ACADIA Pharmaceuticals

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $23.38, for a total value of $162,491.00. Following the sale, the executive vice president owned 7,609 shares of the company’s stock, valued at $177,898.42. The trade was a 47.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 28.30% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ACAD. Amundi acquired a new position in ACADIA Pharmaceuticals during the second quarter worth about $433,000. Cetera Investment Advisers boosted its stake in shares of ACADIA Pharmaceuticals by 7.9% during the 2nd quarter. Cetera Investment Advisers now owns 12,763 shares of the biopharmaceutical company’s stock worth $275,000 after acquiring an additional 931 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $257,000. Quarry LP acquired a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter worth approximately $243,000. Finally, Captrust Financial Advisors purchased a new position in ACADIA Pharmaceuticals in the 4th quarter valued at approximately $220,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.